Novel Treatment for Lung Diseases by Allogeneic Cell Transplantation (No. T4-1868)
Lead Researcher: Prof. Yair Reisner
The treatment of respiratory conditions is currently one of the major challenges to health care systems all over the world. The problem is that most therapeutics currently available for treating pulmonary indications are non-curative, and simply improve symptoms. Presently the only cure for late stage pulmonary diseases is a lung transplant, which includes its own host of problems ranging long waitlists to lifelong immunosuppression. These issues explain why pulmonary diseases represent the second leading cause of death in the world. Therefore, a strong need exists for alternative therapeutic options in treating pulmonary related diseases.
Prof. Yair Reisner and his research group have developed a unique set of methods for culturing and transplanting cells for use in treating respiratory illnesses. Their innovation was not simply an improvement in terms of symptoms but actually showed effective lung repair in mouse models.
? Treatment of lung indications
? Protocol developed such that the method is compatible with donor (allogeneic) cells
The Reisner research group has developed two methods for cell transplantation to repair pulmonary diseases. The first method involves incubating a suspension of fetal pulmonary tissue that is developed to a gestation period of about 20-22 weeks. The reason being is that this acts as the optimal gestation window, where the cells show the high amount of different types of pulmonary progenitor cells. When transplanted into lung damaged mouse models, the cells differentiated and incorporated themselves into the lung, forming fully functional units.
The second method involves sourcing a specific hematopoietic stem cell population from fetal lung. Following a thorough understanding of the therapeutic potential of the cells, in their capacity to develop into the desired lineages. The Reisner group developed a protocol in which the transplantation of allogeneic cells was feasible but did not require long-term immunosuppression. Such that the mouse models showed an ability to develop immunotolerance to said donor cells, and achieved lung repair.